Αρχική World News Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who... World News Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors Από Ogkologos - 23 Σεπτεμβρίου, 2025 435 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Increased Risk of Haematologic Malignancies Among Children and Adolescents Exposed to... 7 Οκτωβρίου, 2025 “Hero” Nurses Plan Wedding In 24 Hours So Dying Patient Can... 10 Μαΐου, 2019 Ex-NFL Player Pays For 500 Mammograms To Honor Late Mom Who... 22 Οκτωβρίου, 2019 Analysis Shows Women with High Breast Cancer Recurrence Scores Benefit from... 24 Οκτωβρίου, 2019 Φόρτωση περισσοτέρων HOT NEWS Dual-Function Virus Engineered to Kill Tumor Cells and Support Immune Cells UK health inequalities: 20,000 more cancer cases a year in the... When Both Tumour-Infiltrating Lymphocytes and Gene Expression are Available, the Prognostic... FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma